SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Clarksterh who wrote (321)11/15/2007 10:28:25 PM
From: mlrb2113  Read Replies (1) of 332
 
8-K looks a little more sinister than that, I think:

Consistent with our agreement last week with the U.S. Food and Drug Administration (FDA) to remove the 300mg dose of AGI-1067 from our ANDES clinical trial, the FDA has formally notified the Company that it is issuing a partial clinical hold on the 300mg dose. A partial clinical hold will require the Company to obtain prior approval from the FDA before commencing any further testing of the 300mg dose. The ANDES trial is continuing with the 150mg and 75mg doses.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News